BIGG

Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence

Rossing, Peter; Caramori, Luiza M; Chan, Juliana C. N; Earley, Amy; de Boer, Ian H.

Kidney int; 102 (5), 2022

The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD) represents a focused update of the KDIGO 2020 guideline on the topic. The guideline targets a broad audience of clinicians treating people with diabetes and CKD. ...

Insuficiencia Renal Crónica/tratamiento farmacológico, Diabetes Mellitus Tipo 2/prevención & control, Automanejo, Control Glucémico, Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico, Antagonistas de Receptores de Angiotensina/uso terapéutico, Inhibidores del Cotransportador de Sodio-Glucosa 2/uso terapéutico

Texto completo

VA/DoD clinical practice guideline for the management of headache

U.S. Government. USA Department of Defense. USA Department of Veterans Affairs.

The VA and DoD Evidence-Based Practice Work Group (EBPWG) was established and first chartered in 2004, with a mission to advise the VA/DoD Health Executive Committee “on the use of clinical and epidemiological evidence to improve the health of the population . . .” across the Veterans Health Administ...

Cefalea/tratamiento farmacológico, Cefalea/clasificación, Atención Dirigida al Paciente/normas, Estimulación Eléctrica Transcutánea del Nervio, Antagonistas de Receptores de Angiotensina/uso terapéutico, Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico, Antidepresivos/uso terapéutico, Anticonvulsivantes/uso terapéutico, Antagonistas Adrenérgicos beta/uso terapéutico, Cefalea/terapia

Texto completo

Chronic kidney disease: assessment and management: Last updated 24 November 2021

England. National Institute for Health and Care Excellence.

This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD. NICE has produce...

Insuficiencia Renal Crónica/prevención & control, Insuficiencia Renal Crónica/complicaciones, Hiperfosfatemia/prevención & control, Antagonistas de Receptores de Angiotensina/uso terapéutico, Monitoreo Ambulatorio de la Presión Arterial/normas

Texto completo (enlace principal) Texto completo (enlace alternativo)

Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practice guideline from the American College of Physicians

Qaseem, A; Hopkins, RH Jr; Sweet, D. E; Starkey, M; Shekelle, P.

Ann. intern. med; 159 (12), 2013

DESCRIPTION: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the screening, monitoring, and treatment of adults with stage 1 to 3 chronic kidney disease. METHODS: This guideline is based on a systematic evidence review eval...

Insuficiencia Renal Crónica/diagnóstico, Insuficiencia Renal Crónica/tratamiento farmacológico, Progresión de la Enfermedad, Triaje, Antagonistas de Receptores de Angiotensina/uso terapéutico, Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico, Antihipertensivos/uso terapéutico, Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico, Hipolipemiantes/uso terapéutico, Gemfibrozilo/uso terapéutico, Enfermedades Asintomáticas, Quimioterapia Combinada, Enfoque GRADE

Texto completo